Nifty 17053.95 (0.16%)
Sensex 57260.58 (0.27%)
Nifty Bank 35976.45 (-0.14%)
Nifty IT 34870.75 (0.76%)
Nifty Financial Services 17629.95 (0.09%)
Adani Ports 702.60 (-2.03%)
Asian Paints 3144.30 (0.04%)
Axis Bank 651.10 (-1.61%)
B P C L 367.45 (-2.49%)
Bajaj Auto 3298.20 (-1.09%)
Bajaj Finance 6905.75 (1.45%)
Bajaj Finserv 16890.40 (1.25%)
Bharti Airtel 739.35 (0.08%)
Britannia Inds. 3528.60 (-0.75%)
Cipla 965.00 (-0.18%)
Coal India 154.25 (-1.06%)
Divis Lab. 4921.35 (-0.33%)
Dr Reddys Labs 4697.60 (-1.12%)
Eicher Motors 2413.40 (-0.84%)
Grasim Inds 1683.95 (-0.36%)
H D F C 2713.80 (-1.02%)
HCL Technologies 1133.15 (2.08%)
HDFC Bank 1501.25 (0.76%)
HDFC Life Insur. 683.65 (1.94%)
Hero Motocorp 2490.80 (-1.53%)
Hind. Unilever 2329.40 (-0.24%)
Hindalco Inds. 420.15 (0.76%)
I O C L 118.80 (-1.78%)
ICICI Bank 718.40 (-0.53%)
IndusInd Bank 895.45 (-0.70%)
Infosys 1696.35 (0.28%)
ITC 221.50 (-1.12%)
JSW Steel 625.60 (-0.49%)
Kotak Mah. Bank 2019.60 (2.82%)
Larsen & Toubro 1767.25 (-0.61%)
M & M 850.80 (-0.35%)
Maruti Suzuki 7149.50 (-0.29%)
Nestle India 19000.40 (-1.15%)
NTPC 126.50 (-1.82%)
O N G C 144.10 (-2.04%)
Power Grid Corpn 200.25 (-0.87%)
Reliance Industr 2441.50 (1.20%)
SBI Life Insuran 1136.25 (0.52%)
Shree Cement 25540.05 (-1.56%)
St Bk of India 465.10 (-1.15%)
Sun Pharma.Inds. 751.05 (-2.12%)
Tata Consumer 766.00 (-0.09%)
Tata Motors 461.45 (0.27%)
Tata Steel 1114.75 (0.22%)
TCS 3502.00 (1.60%)
Tech Mahindra 1536.65 (0.61%)
Titan Company 2324.20 (1.39%)
UltraTech Cem. 7388.25 (-0.09%)
UPL 689.35 (-2.05%)
Wipro 630.60 (1.47%)
INFY

Nectar Lifesciences Ltd.

₹23.8
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Nectar Lifesci.

  • Master Rating:
  • Nectar Lifesciences has an operating revenue of Rs. 1,476.40 Cr. on a trailing 12-month basis. An annual revenue de-growth of -35% needs improvement, Pre-tax margin of -5% needs improvement, ROE of -6% is poor and needs improvement. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 144 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Nectar Lifescience Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Nectar Lifescience Ltd Synopsis

NSE-Medical-Generic Drugs

Nectar Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1541.82 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2021. Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664.
  • Market Cap

    INR 533.74 Cr

  • Sales

    INR 1,475.76 Cr

  • Shares in Float

    12.56 Cr

  • No of Funds

    6 K

  • Yield

    0.22%

  • Book Value

    0.5

  • U/D Vol Ratio

    1

  • LTDebt/Equity

    12%

  • Alpha

    0.09

  • Beta

    0.79

Nectar Lifescience Ltd Ownership
Nectar Lifescience Ltd Management

Nectar Lifescience Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 1060.7311134.6051104.6371058.6291006.727
Fixed Assets Annual Cr 870.517899.846924.368952.141983.354
Total Non Current Assets Annual Cr 981.5421018.4881036.2881063.5431085.385
Total Current Assets Annual Cr 1488.6551613.6791667.4881660.3511495.665
Total Assets Annual Cr 2470.1972632.1672703.7762723.8942581.05
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 47.299150.593249.256947.205444.891
ROE Annual % -6.892.644.284.925.47
ROCE Annual % 4.111.6714.7112.5614.17
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 7.329.49.6912.915.02

Nectar Lifescience Ltd Technicals

EMA & SMA

CURRENT PRICE

23.8 (-4.8)

    • Bullish Moving Averages 0
    • Bearish Moving Averages 16

EMA

  • 20 Day

    25.66

  • 50 Day

    27.6

  • 100 Day

    28.69

  • 200 Day

    28.93

Nectar Lifescience Ltd Resistance and support

25.34 PIVOT

  • First Resistance

    26.07

  • Second Resistance

    27.14

  • Third Resistance

    27.87

  • First Support

    24.27

  • Second Support

    23.54

  • Third Support

    22.47

  • RSI

    32.42

  • MFI

    30.83

  • MACD

    -1.07

  • MACD signal line

    -1.08

Nectar Lifescience Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 429,615 20,118,870 46.83%
Week 391,477 19,511,234 49.84%
1 Month 314,856 18,938,576 60.15%
6 Month 1,337,205 63,945,152 47.82%

Nectar Lifescience Ltd Price change analysis

-2.6

Over 1 month

Low High
23.1 27.9

-7.9

Over 3 month

Low High
23.1 34.15

-7.9

Over 6 months

Low High
23.1 48.4

5.5

Over Year

Low High
18.3 48.4

Similar Stocks

News

NECTAR LIFESCIENCES LTD. - 532649 - Announcement under Regul

We are furnishing herewith newspaper copy of Publication of Financial Results of the Company for the quarter ended on September 30, 2021, wh Read More

Nectar Lifesciences Ltd - 532649 - Outcome Of Board Meeting

Nectar Lifesciences Limited has informed the Exchange regarding ''Outcome of Board Meeting and Sale of Non-Core Assets/ Core Assets which ar Read More

NECTAR LIFESCIENCES LTD. - 532649 - Unaudited Financial Resu

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Read More

Nectar Lifesciences Ltd - 532649 - Board Meeting Intimation

NECTAR LIFESCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2021 ,inter alia, t Read More

Nectar Lifesciences Ltd - 532649 - Shareholding for the Peri

Nectar Lifesciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Clic Read More

Blogs

FAQs